Zum Inhalt springen

Neue KI-gestützte biomedizinische Wissensdatenbank: QIAGEN beschleunigt datenbasierte Arzneimittelforschung

QIAGEN Biomedical KB-AI enthält mehr als 640 Millionen biomedizinische Beziehungen, darunter Kausalzusammenhänge zwischen Genen, Krankheiten und Medikamenten, zur Beschleunigung der datenbasierten Arzneimittelforschung // Ergänzt von Menschen kuratierte QIAGEN Biomedical KB-HD und hilft bei der Identifizierung neuer Zusammenhänge zwischen Krankheiten, biologischen Signalwegen und molekularen Wechselwirkungen, die mit herkömmlichen Methoden übersehen werden können // Workflow verkürzt die Hypothesenprüfung und beschleunigt die Identifizierung vielversprechender therapeutischer Wege mit klaren, strukturierten Daten Neue KI-gestützte biomedizinische Wissensdatenbank: QIAGEN beschleunigt datenbasierte Arzneimittelforschung

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Highlights: Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data… 

more »QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

FDA Grants Fast Track Designation to 9MW2821

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as „ESCC“).

Tränenflüssigkeit verrät Schlaganfall-Risiko

Forschende der Uni Bonn haben einen nicht-invasiven, schmerzfreien Ansatz entwickelt, der eine Schlaganfall-Gesundheitsrisikobewertung durch Tränenflüssigkeit, Mitochondrien als lebenswichtigen Biosensor und eine KI-gestützte Dateninterpretation nutzt. „Mitochondrien sind in jeder Zelle unseres Körpers vorhanden und fungieren als lebenswichtiger Partner und strenger Beobachter, ob mit unserer Gesundheit alles stimmt.“, erklärt Olga Golubnitschaja, Leiterin der Forschungsgruppe für 3P (prädiktive, präventive und personalisierte) Medizin des Universitätsklinikums Bonn (UKB). „Wenn etwas nicht in Ordnung ist, melden sich die Mitochondrien durch Mitophagie und signalisieren an alle Systeme, dass wir ein gesundheitliches Problem haben. Diese Signale sind objektiv anhand von Flüssigbiopsien messbar.“ Durch die nicht-invasive und für den Betroffenen schmerzfreie Entnahme der Tränenflüssigkeit, kann somit ein individuelles Profil der Patienten und Patientinnen erstellt werden. Publikation: Olga Golubnitschaja et al.; The paradigm change from reactive medical services to 3PM in ischemic stroke: A holistic approach utilising tear fluid multi-omics,… 

more »Tränenflüssigkeit verrät Schlaganfall-Risiko

Blockchain technology balances privacy with regulatory compliance

Blockchain’s inherent transparency, while beneficial for validation and trust, poses significant privacy concerns. Traditional transactions on public blockchains are permanently visible, compromising user privacy. This visibility has been a double-edged sword, providing transparency but at the cost of personal data exposure. A new protocol called Privacy Pools offers a potential solution to the seemingly contradictory goals of blockchain privacy and regulatory compliance. In a recent study ( doi: https://doi.org/10.1016/j.bcra.2023.100176 ) published in Blockchain: Research and Applications on 21 February 2023, contributed by Vitalik Buterin (co-founders of Ethereum), Jacob Illum, Matthias Nadler, Fabian Schär, and Ameen Soleimani. The researchers have developed a protocol called „Privacy Pools“ that enhances privacy on blockchain transactions while complying with regulatory standards. This new smart contract-based protocol enables users to prove specific attributes of their transactions without exposing their entire history, maintaining both privacy and transparency.

Des peptides cycliques pour des médicaments moins onéreux

Une équipe de chercheurs de l’Université de Bath a mis au point un nouvel outil pour  le développement de nouveaux traitements pharmaceutiques de manière plus écologique et moins coûteuse. Leur innovation repose sur l’utilisation de protéines cycliques, une approche alternative aux molécules conventionnelles, dans la fabrication de médicaments.  Traditionnellement, les traitements médicamenteux interagissent avec des […] Des peptides cycliques pour des médicaments moins onéreux

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy (epinephrine nasal spray), an investigational new drug. The trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch, hives, urticaria and erythema scores as early as 5 minutes after dosing. Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy. ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study